Submit request or call to make an appointment.
Norton Children’s Cancer Institute, affiliated with the UofL School of Medicine, offers CAR-T cell therapy for children and teens with fairly advanced and/or recurrent B-cell acute lymphoblastic leukemia (ALL). CAR-T cell therapy is a newer approach to cancer treatment that uses the body’s own immune cells to kill cancerous cells. Norton Children’s Cancer Institute is the only pediatric program in Kentucky offering CAR-T cell therapy.
CAR-T cell therapy was approved by the U.S. Food and Drug Administration (FDA) for treating relapsed B-cell ALL in 2017. At this time, CAR-T cell therapy is not used for other types of leukemia or childhood cancer, but research is ongoing to expand this therapy to other types of childhood cancer.
CAR-T cell therapy is an immunotherapy in which the body’s immune system is activated to fight off disease. CAR-T cell therapy teaches the body’s immune system to recognize and eliminate cancerous B cells, which can help the body control the growth of cancer cells over time.
CAR-T cell therapy works as follows:
Children and teens who receive CAR-T cell therapy will continue to be monitored for side effects after therapy.
Families are encouraged to ask about potential benefits of cellular therapy early on during a child’s cancer treatment process. For CAR-T cell therapy, collecting cells from a patient before serious illness and/or intensive chemotherapy can help the therapy be as successful as possible.
About 85% of ALL cases are successfully treated with standard chemotherapy. However, in the other 15% of cases, chemotherapy works temporarily or not at all. CAR-T cell therapy is not a treatment for newly diagnosed leukemia — only for patients whose ALL is not responding to chemotherapy and the disease may have returned after a bone marrow transplant.